前列腺特异性膜抗原PET:前列腺癌的临床应用、正常表现、要点与陷阱
本文综述前列腺特异性膜抗原(PSMA)PET在前列腺癌中的应用,指出镓68-PSMA-11是最广泛使用的示踪剂,PSMA PET较传统影像具有更高敏感度和特异度,常可检出亚厘米病灶,适用于前列腺、淋巴结、软组织和骨的一站式成像,但关于改善患者结局的证据仍缺乏,需熟悉其生理分布及假阳性原因。
要点
- PSMA PET较传统影像敏感度和特异度更高,常可检出亚厘米前列腺癌病灶。
- PSMA并非前列腺特异,在多种正常组织及良性、恶性病变中表达,需掌握生理分布以减少假阳性。
- PSMA PET可用于高危初诊分期和生化复发定位,但在早期生化复发和寡转移靶向治疗中改善结局的证据仍缺乏。
核心结论
- PSMA PET较传统影像具有更高敏感度和特异度,常可检出亚厘米病灶,可用于前列腺、淋巴结、软组织和骨的一站式成像;在高危初诊分期和生化复发定位中有临床价值,但在转移性去势抵抗性前列腺癌中主要用于诊疗一体化选择,治疗监测价值仍有争议,改善患者结局的证据仍缺乏。
研究设计与样本
- 综述,检索范围与纳入文献原文未报告。
临床应用与阅片要点
- PSMA PET较传统影像具有更高敏感度和特异度,常可检出小体积病变,正在重新定义疾病播散模式;需掌握其生理分布及其他摄取原因以减少假阳性;在转移性去势抵抗性前列腺癌中常用于诊疗一体化选择(如镥177-PSMA放射性核素治疗),但其治疗监测的潜在用途仍有争议。
局限性
- 关于PSMA PET改善患者相关结局的适当使用证据仍缺乏,尤其是在早期生化复发和寡转移性疾病靶向治疗的情况下。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein that is overexpressed in prostate cancer. Radiolabeled small molecules that bind with high affinity to its active extracellular center have emerged as a potential new diagnostic standard of reference for prostate cancer, resulting in images with extraordinary tumor-to-background contrast. Currently, gallium 68 (68Ga)-PSMA-11 (or HBED-PSMA) is the most widely used radiotracer for PSMA positron emission tomography (PET)/computed tomography (CT) or PSMA PET/magnetic resonance (MR) imaging. Evolving evidence demonstrates superior sensitivity and specificity of PSMA PET compared to conventional imaging, with frequent identification of subcentimeter prostate cancer lesions. PSMA PET is effective for imaging disease in the prostate, lymph nodes, soft tissue, and bone in a "one-stop-shop" examination. There is emerging evidence for its clinical value in staging of high-risk primary prostate cancer and localization of disease in biochemical recurrence. The high sensitivity provided by PSMA PET, with frequent identification of small-volume disease, is redefining patterns of disease spread compared with those seen at conventional imaging. In metastatic castration-resistant prostate cancer, PSMA PET is frequently used for theranostic selection (eg, lutetium 177-PSMA radionuclide therapy), but its potential use for therapy monitoring is still under debate. However, evidence on its proper use to improve patient-related outcomes, particularly in the setting of early biochemical recurrence and targeted treatment of oligometastatic disease, is still missing. Despite the term prostate specific, PSMA functions as a folate hydrolase and is expressed in a range of normal tissues and in other benign and malignant processes. Knowledge of its physiologic distribution and other causes of uptake is essential to minimize false-positive imaging findings. ©RSNA, 2018.
引用
- Hofman MS, Hicks RJ, Maurer T, et al. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. Radiographics. 2018. PMID: 29320333. doi:10.1148/rg.2018170108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。